GLPGF — Lakefront Biotherapeutics NV
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1421876 ·
Belgium
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 12,110,000 | 2,965,000 | -43,511,000 | 2,109,000 | 3,351,188,000 | 135,952,000 | 87,558,000 |
| Mar 2026 | 6,481,000 | 1,682,000 | -63,703,000 | 14,492,000 | 3,372,429,000 | 66,805,000 | 119,060,000 |
| Dec 2025 | 900,822,000 | 900,367,000 | 758,798,000 | 782,146,000 | 3,406,518,000 | 87,868,000 | 170,650,000 |
| Sep 2025 | 71,161,000 | 60,315,000 | -41,672,000 | -202,111,000 | 3,511,914,000 | 64,458,000 | 1,064,951,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-301,599,000
Investing CF
$265,566,000
Financing CF
$-2,772,000
CapEx
$-8,732,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.11
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$228,331,000
Inventory
$17,693,000
Receivables
$54,034,000
ST Investments
$2,915,435,000
EBIT TTM
$398,093,000
Pretax Income TTM
$471,194,000
Interest Exp TTM
$97,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$990,574,016
EBITDA
$568,918,016
Free Cash Flow
$138,206,256
Enterprise Value
$-510,395,424
Total Cash
$2,239,548,928
Total Debt
$6,362,000
Shares Out
65,484,670
Trailing EPS
$10.49
Book Value
$57.73
ROE
20.1%
ROA
9.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,112,248,000 | 501,391,000 | 320,884,000 | 3,406,518,000 | 170,650,000 | 3,235,868,000 | -257,456,000 |
| Dec 2024 | 275,649,000 | -188,338,000 | 74,082,000 | 4,135,719,000 | 1,238,780,000 | 2,896,939,000 | -320,026,000 |
| Dec 2023 | 239,724,000 | -88,263,000 | 211,697,000 | 4,357,396,000 | 1,561,830,000 | 2,795,566,000 | -405,970,000 |
| Dec 2022 | 241,249,000 | -131,057,000 | -217,991,000 | 4,734,351,000 | 2,208,325,000 | 2,526,026,000 | -500,544,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says
2026-09-23 15:00 · Yahoo
Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls
2026-09-23 13:49 · Yahoo
Acquisition of Own Shares
2026-09-22 20:01 · Yahoo
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig
2026-09-21 09:02 · Yahoo
Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
2026-09-08 20:01 · Yahoo
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
2026-09-04 22:14 · Yahoo
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
2026-08-24 20:01 · Yahoo
Lakefront Receives Transparency Notification from Bank of America
2026-08-24 20:01 · Yahoo
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
2026-08-10 20:01 · Yahoo
Galapagos Q1 Earnings Call Highlights
2026-05-07 20:58 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.